1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. Austria >
  5. neuraxpharm Acquires Easypharm OTC

M&A Deal Summary

neuraxpharm Acquires Easypharm OTC

On January 22, 2020, neuraxpharm acquired life science company Easypharm OTC

Acquisition Highlights
  • This is neuraxpharm’s 1st transaction in the Life Science sector.
  • This is neuraxpharm’s 1st transaction in Austria.

M&A Deal Summary
Date 2020-01-22
Target Easypharm OTC
Sector Life Science
Buyer(s) neuraxpharm
Deal Type Add-on Acquisition

Target

Easypharm OTC

Gießhübl, Austria
Easypharm OTC GmbH is a consumer healthcare company. easypharm focuses purely on Consumer Healthcare via, among others, its two leading CNS brands, easysleep®, and easyrelax®. Easypharm OTC GmbH was established in 2008 and is based in Gießhübl, Austria.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

neuraxpharm

Langenfeld, Germany
Category Company
Founded 1985
Sector Life Science
Revenue 460M EUR (2019)
DESCRIPTION

neuraxpharm is a provider of generic pharmaceutical products for the treatment of disorders of the central nervous system (CNS). neuraxpharm was formed in 1985 and is based in Langenfeld, Germany.

DEAL STATS #
Overall 1 of 4
Sector: Life Science M&A 1 of 3
Type: Add-on Acquisition M&A Deals 1 of 3
Country: Austria M&A 1 of 1
Year: 2020 M&A 1 of 3
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-09-14 Takeda Pharmaceutical Co. - Buccolam

Osaka, Japan

Takeda Pharmaceutical Co. Ltd. - Buccolam is the only buccal midazolam approved across Europe. This value-added product is indicated for the emergency treatment of epileptic children with prolonged acute convulsive seizures (PACS), the most common neurological emergency in children with an incidence of 18 to 23 cases per 100,000 per year.

Buy -
Mergr

Solution for

Product

Company

Legal